Type 2 diabetes mellitus is a recognized risk factor for HCC in patients with liver disease,
independent from the etiology of their liver disease. Hence, prevention and treatment of type …

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver
transplantation (LT) in Western Countries, both for end stage liver disease and …

Type 2 diabetes mellitus is a recognized risk factor for HCC in patients with liver disease,
independent from the etiology of their liver disease. Hence, prevention and treatment of type …

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

Although liver transplantation (LT) recipients are at high cardiovascular risk (CVR), the
management of CVR factors (CVRF) after LT is far from optimal and needs to be improved …

Outcomes after liver transplantation have continuously improved over the past decades, but
long-term survival rates are still lower than in the general population. The liver has distinct …

Background There is controversy surrounding the association between preexisting frailty
and increased mortality in candidates and recipients of solid-organ transplants. This meta …

Strategies to minimize immune-suppressive medications after liver transplantation are
limited by allograft rejection. Biopsy of liver is the current standard of care in diagnosing …

Background: Liver transplantation (LT) is a routine therapeutic approach for patients with
acute liver failure, end-stage liver disease and/or early-stage liver cancer. While 5-year …

The development of tumors in livers transplanted from hepatitis B virus (HBV)‑negative
donors to patients with hepatitis B and cirrhosis is rare. The present study describes the case …